Answers are grounded in this paper and cite their sources.
Commentary on: Tricco AC, Soobiah C, Berliner S, et al. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ 2013;185:1393–401.[OpenUrl][1][Abstract/FREE Full Text][2] Dementia is a chronic disease with insidious onset. Thus, Alzheimer disease can be present years, or even decades, before the clinical onset of Alzheimer dementia .1 ,2 Much research attention is being paid to biomarkers which, singly or in combination, may help identify which patients will go on to develop Alzheimer dementia while they are still asymptomatic, but their predictive validity is still inadequate.3 Many patients seen in clinical practice fall into the grey area of having some, relatively minor, memory problems which have little impact on their day-to-day functioning. These criteria are at the core … [1]: {openurl}?query=rft.jtitle%253DCMAJ%26rft_id%253Dinfo%253Adoi%252F10.1503%252Fcmaj.130451%26rft_id%253Dinfo%253Apmid%252F24043661%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/ijlink?linkType=ABST&journalCode=cmaj&resid=185/16/1393&atom=%2Febmed%2F19%2F3%2F101.atom
No takes yet. Share an insight, caveat, or question.
Tom C. Russ (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: